News | February 05, 2022
Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
This surpasses the number of approvals supported in 2020
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
Subscribe To Our Newsletter & Stay Updated
